title: High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potential.
abstract: We investigated the potential of various cytostatic agents for preventing graft rejection following allogeneic bone marrow transplantation. LEW rats received a lethal dose (35 mg/kg) of busulfan followed by injection of 1 x 10(8) F1(CAP x LEW) marrow cells, which are unable to induce a graft-versus-host reaction in LEW recipients. Rejection of the marrow graft was assessed by monitoring haematocrit and granulocyte counts. Due to its weak immunosuppressive activity, busulfan by itself is unable to allow engraftment of allogeneic marrow. Therefore, agents administered in addition to busulfan can be tested for their capacity to prevent marrow graft rejection. 120 mg/kg of cyclophosphamide, 20 mg/kg of ACNU and 240 mg/kg of ifosfamide completely prevented rejection of the allogeneic marrow. Maximum doses of BCNU applicable in conjunction with busulfan reduced the rejection rate to 12% (30 mg/kg) and 17% (40 mg/kg), whereas the antitumour agents thiotepa, melphalan, and carboplatin exhibited a very limited engraftment-promoting potential in this experimental setting. Thus, BCNU (carmustine), ACNU (nimustine), and ifosfamide might be suitable candidates for conditioning of allogeneic bone marrow graft recipients.
authors.affiliation: Second Department of Internal Medicine, University of Kiel, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: L
authors.initials: L
authors.lastname: Uharek
authors.forename: A
authors.initials: A
authors.lastname: Erbersdobler
authors.forename: B
authors.initials: B
authors.lastname: Glass
authors.forename: H U
authors.initials: HU
authors.lastname: Wottge
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: H
authors.initials: H
authors.lastname: Löffler
authors.forename: W
authors.initials: W
authors.lastname: Mueller-Ruchholtz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016026:Bone Marrow Transplantation; D016190:Carboplatin / Q000494:pharmacology; D002330:Carmustine / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D006084:Graft Rejection / Q000187:drug effects*; D007069:Ifosfamide / Q000494:pharmacology; D007165:Immunosuppression Therapy; D008297:Male; D008558:Melphalan / Q000494:pharmacology; D015376:Nimustine / Q000494:pharmacology; D051381:Rats; D011917:Rats, Inbred Lew; D013852:Thiotepa / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D015376:Nimustine; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D008558:Melphalan; D002330:Carmustine; D007069:Ifosfamide